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ABSTRACT 
Objective. Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune 
tolerance in ovarian cancer. This study investigated efficacy and safety of the IDO1 
enzyme inhibitor epacadostat versus tamoxifen in patients with biochemical-only 
recurrence (CA-125 elevation) following complete remission after first-line 
chemotherapy for advanced epithelial ovarian, primary peritoneal, or fallopian tube 
cancer. 
Methods. In this open-label, phase 2 study (NCT01685255), patients were 
randomised 1:1 to epacadostat 600 mg or tamoxifen 20 mg twice daily for 
successive 28-day cycles and stratified by time since completion of first-line 
chemotherapy to first CA-125 elevation (3 to <12 or ≥12 months). The primary 
endpoint was investigator-assessed progression-free survival (PFS; RECIST v1.1). 
Secondary endpoints included CA-125 response (Gynecologic Cancer InterGroup 
criteria), overall survival, safety, and tolerability. 
Results. The study was terminated primarily due to slow accrual and lack of 
evidence of superiority. Median PFS was 3.75 months for epacadostat (n=22) versus 
5.56 months for tamoxifen (n=20; HR, 1.34 [95% CI, 0.58–3.14]; P=0.54). Of 
evaluable patients, 1 (5.0%) epacadostat and 3 (15.8%) tamoxifen patients had 
confirmed CA-125 responses. The most common treatment-emergent adverse event 
was fatigue (epacadostat, 36.4%; tamoxifen, 40.0%). Immune-related adverse 
events, observed with epacadostat only, were primarily rash (18.2%) and pruritus 
(9.1%). Epacadostat pharmacokinetics/pharmacodynamics were consistent with its 
known mechanism of action. IDO1 expression was observed in 94% of archival 
tumour samples. 
 4 
Conclusions. This first report of immunotherapy evaluation in biochemical-only 
relapse ovarian cancer and of IDO1 inhibitor monotherapy in ovarian cancer found 
no significant difference in efficacy between epacadostat and tamoxifen. 
Epacadostat was generally well tolerated. 
Abstract word count, 253 (limit, 250) 
Keywords (limit, 6): epacadostat; ovarian cancer; tamoxifen; CA-125; IDO1 enzyme 
inhibitor  
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INTRODUCTION 
Ovarian cancer is the leading cause of gynaecologic cancer-related deaths 
worldwide and has poor long-term survival [1-3]. For patients who relapse ≥6 months 
after responding to first-line treatment (typically cytoreductive surgery and systemic 
platinum-based chemotherapy [2,4]), retreatment with platinum-based chemotherapy 
has encouraging response rates [5]; however, the majority of patients experiencing 
relapse are considered incurable [2,4,6]. There remains a substantial unmet clinical 
need for better strategies to improve disease-free survival and cure in early 
treatment of ovarian cancer [5,6]. 
The development of symptoms is one indicator of disease relapse, prompting 
biochemical testing with the tumour marker CA-125 and imaging to confirm disease 
recurrence [5,7]. However, patients are frequently asymptomatic at the time of small-
volume recurrence, with suspicion of relapse based solely on rising CA-125 levels 
[5,7]. In such patients, a watch-and-wait policy is justifiable. Second-line 
chemotherapy is initiated according to symptoms, extent of disease and CA-125 
level, among other considerations [5]. When patients present with a biochemical 
relapse without clinical evidence of disease, there may be an opportunity to improve 
outcomes by extending the time that the cancer remains under control, potentially 
delaying progression and the need for further cytotoxic therapy.  
Ovarian cancer is an immunogenic malignancy [8,9], supporting the rationale for 
immunomodulatory agents (eg, checkpoint inhibitors) as potentially effective 
therapeutic agents. Recruitment of regulatory T cells in ovarian cancer leads to 
immunosuppression [10], which has been associated with decreased survival, 
paclitaxel resistance, and increased levels of vascular endothelial growth factor 
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[8,10]. In patients with stage III/IV ovarian cancer, survival is also strongly correlated 
with the presence of tumour-infiltrating lymphocytes (TILs) [11], with a 5-year survival 
of 38% when TILs are present versus 4.5% when they are absent [12]. 
The intracellular indoleamine 2,3-dioxygenase-1 (IDO1) enzyme is a key regulator of 
the immunosuppression responsible for tumour escape from immune surveillance 
[15-17] and is predominantly expressed by tumour epithelial cells, antigen-presenting 
cells in primary tumours and tumour-draining lymph nodes in a variety of cancers 
[13,14]. IDO1 catalyses the degradation of tryptophan via oxidation to kynurenine 
(Kyn), which results in strong inhibitory effects on T-cell–mediated responses, 
including blocking T-cell activation and inducing T-cell apoptosis [18]. High 
intratumoural IDO1 expression in ovarian cancer has been found to correlate with a 
reduced number of TILs [19], advanced disease stage, paclitaxel resistance, and 
decreased survival [15-17,19]. Taken together, these findings strongly support IDO1 
as a rational target to reactivate the antitumour immunity in patients with ovarian 
cancer. Epacadostat (INCB024360), a selective IDO1 enzyme inhibitor, has been 
developed and is currently under clinical investigation in various tumour types [20-
23].  
Ovarian cancer treatment guidelines suggest that patients with biochemical relapse 
(serially increasing CA-125 levels and no clinical evidence of disease) have several 
options: (1) delay therapy until clinical relapse; (2) enrol in a clinical trial; or (3) 
undergo treatment with a second-line therapy that has an acceptable side-effect 
profile, such as biologic therapies (eg, tamoxifen) over cytotoxic therapies [2]. We 
hypothesised that these patients would be good candidates for immune-targeted 
therapies and investigated the effects of treatment with epacadostat in patients with 
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a low cancer burden. Thus, the objective of this study was to determine the efficacy 
of epacadostat compared with tamoxifen in biochemical-recurrent–only epithelial 
ovarian, primary peritoneal, or fallopian tube cancer. 
 
METHODS 
Study Design and Treatment 
This international, multicentre, randomised, open-label phase 2 study conducted in 6 
countries (United States, United Kingdom, Russia, Ukraine, Australia, and Canada) 
evaluated epacadostat versus tamoxifen for efficacy, safety, and tolerability in 
women with ovarian cancer and CA-125 elevation following complete remission with 
first-line chemotherapy. At study initiation, the intention was to enrol 110 patients 
randomised 1:1 to receive epacadostat or tamoxifen and stratified based on the 
number of months since prior first-line chemotherapy to the time of their first CA-125 
elevation (3 to <12 months or ≥12 months). The study (ClinicalTrials.gov: 
NCT01685255) was conducted in accordance with the ethical principles of Good 
Clinical Practice, according to the International Conference on Harmonisation 
guidelines, and was approved by the institutional review board or ethics committee at 
each participating institution. All patients provided written informed consent before 
initiation of treatment. 
Study treatment was administered orally as continuous 28-day cycles of either 
epacadostat 600 mg twice daily (BID) or tamoxifen 20 mg BID. Dose reductions, 
interruptions, or discontinuations were allowed at any time for safety reasons 
(Supplement Table 1). However, only 2 dose reductions of epacadostat were 
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allowed (400 mg BID and 300 mg BID). The study comprised a screening phase, 
treatment phase, and safety follow-up phase. During the treatment phase, patients 
received study drug in successive 28-day cycles until they met any criterion for 
withdrawal. Patients were monitored for 60 days after the last dose of epacadostat or 
tamoxifen during the safety follow-up. After this, patients were monitored for survival 
at approximately 12-week intervals.  
Study Population 
Eligible patients were women aged 18 years or older with Eastern Cooperative 
Oncology Group performance status 0 or 1; histologically confirmed Federation of 
International Gynecologists and Obstetricians (FIGO) [24] stage IC, II, III, or IV 
epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer at 
diagnosis; biochemical recurrence; and no other objective evidence of disease 
recurrence as defined by Response Evaluation Criteria in Solid Tumors (RECIST 
v1.1). Biochemical recurrence of disease (Gynecologic Cancer InterGroup [GCIG] 
criteria) was defined as 2 consecutive measurements of CA-125 above the upper 
limit of normal (ULN) that were ≥2 weeks apart, with the second measurement 
showing a further increase from the first measurement. If the first CA-125 
measurement is ≥2× ULN, the confirmatory CA-125 measurement only needs to be 
≥1 week later. In the United Kingdom (UK-only requirement), biochemical recurrence 
of disease was defined as elevated CA-125 levels ≥2× ULN on 2 occasions that 
were ≥1 week apart without evidence of disease as defined by RECIST 1.1. Before 
entering the study, patients must have had a complete response to chemotherapy 
and must have received a first-line platinum-containing chemotherapy regimen with 
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documentation of CA-125 elevation at first diagnosis and at least 1 normal CA-125 
level during or after first-line therapy. 
Key exclusion criteria included protocol-specified active or inactive autoimmune 
processes (except vitiligo, thyroiditis, or eczema) and unstable cardiovascular 
disease ≤6 months before starting study treatment. Patients were also excluded if 
they had received prior antitumour systemic therapy besides first-line chemotherapy; 
prior radiotherapy within 3 months of randomisation with unresolved toxicities; prior 
investigational drug or immunologically based treatment for any reason, including 
chronic use of systemic steroid ≥7.5 mg/d prednisone equivalents (except completed 
adjuvant therapy or use of inhaled or topical steroids); potent cytochrome P450 3A4 
inducers or inhibitors; monoamine oxidase inhibitors within the 21 days before 
screening; prior serotonin syndrome after receiving ≥1 serotonergic drug; and 
contraindication to tamoxifen therapy.  
Endpoints and Assessments 
The primary endpoint was efficacy by investigator-assessed progression-free 
survival (PFS; RECIST v1.1). Per RECIST v1.1, progressive disease was defined by 
the appearance of any new lesion, whether target or non-target. Disease and tumour 
assessments were conducted every 8 weeks for the first 12 months, then every 12 
weeks thereafter, and at end of treatment or early termination. 
Secondary endpoints included evaluation of CA-125 response or non-response 
(GCIG criteria; CA 125 already progressing at study entry), overall survival, and 
evaluation of the safety and tolerability of epacadostat. A CA-125 response (GCIG 
criteria) was defined as ≥50% reduction in CA-125 levels from a pretreatment 
sample that was confirmed and maintained for ≥28 days. Safety and tolerability 
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assessments included treatment-emergent adverse events (TEAEs), treatment-
related adverse events (TRAEs), and immune-related adverse events (irAEs), vital 
signs, electrocardiograms (ECGs), physical examination, and clinical laboratory 
tests. CA-125 and adverse events were assessed at baseline then every 4 weeks 
thereafter, at end of treatment or early termination, and 30 and 60 days after end of 
treatment or last dose. 
Exploratory endpoints included assessment of epacadostat pharmacokinetics (PK) 
and pharmacodynamics (PD). Blood samples for PK assessments were obtained on 
day 15 of cycle 1 and day 1 of cycle 2. Blood samples for PD assessments were 
obtained on days 1 and 15 of cycle 1, day 1 of cycles 2 to 4, every 4 weeks 
thereafter, at end of treatment or early termination, and at follow-up. Following whole 
blood sample stimulation ex vivo with interferon-γ (IFN-γ; 100 ng/mL) and 
lipopolysaccharide (LPS; 100 ng/mL) for approximately 20 hours, plasma levels of 
tryptophan and Kyn were evaluated by liquid chromatography with tandem mass 
spectrometry as previously described [22]. Percentage inhibition of IDO1, as 
determined by the decrease in Kyn levels, was calculated by comparing predose 
values with those obtained at different times after dosing. Changes in plasma levels 
of proteins related to immunity and inflammation were monitored using Evidence 
Investigator™ Biochip Array technology (Randox Laboratories, Crumlin, County 
Antrim, UK), a custom-designed multiplex biochip assay that is based on sandwich 
chemiluminescent immunoassays. Analysis of archival tumour biopsy samples for 
IDO1 and programmed death-ligand 1 (PD-L1) expression was also performed using 
immunohistochemistry. 
Statistical Methods 
 11 
Per protocol, target enrolment was 110 patients (55 per treatment group, with the 
expectation that target enrolment would be reached within 18 months), and a formal 
interim analysis for futility was planned to occur after 30 deaths or disease 
progression events were observed. However, 20 months after the study began, 
actual enrolment was <50% of target enrolment, prompting an earlier, unplanned 
interim analysis. Based on the results of this analysis (42 patients, 26 progression 
events), the sponsor terminated the study for lack of evidence of superiority, and no 
formal interim analysis was conducted. 
The modified intent-to-treat population, defined as all randomised patients who 
received ≥1 dose of study drug, was used for efficacy analyses. Safety analyses 
included all enrolled patients who received ≥1 dose of study drug. The PK/PD 
evaluable population included patients who received ≥1 dose of epacadostat or 
tamoxifen and provided ≥1 postdose plasma sample for PK/PD measurement. 
SAS® software, version 9.2 (SAS Institute, Cary, NC) was used to generate all 
tables, graphs, and statistical analyses. Descriptive statistics were used to present 
summaries of continuous and categorical variables. Safety, PK, PD, and 
immunologic marker data were analysed using summary statistics (eg, means and 
frequencies). 
Standard noncompartmental PK methods were used to analyse epacadostat plasma 
concentration data using Phoenix WinNonlin® version 6.0 (Pharsight Corporation, 
Mountain View, CA). 
 
RESULTS 
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Study Population 
Forty-two women were enrolled in the study between March 7, 2013, and October 
23, 2014 (epacadostat, n=22; tamoxifen, n=20). All 42 patients were evaluated for 
efficacy and safety. All 42 patients discontinued from study drug treatment. The most 
common reason for discontinuation was disease progression (epacadostat, n=10 
[45.5%]; tamoxifen, n=11 [55.0%]). Six patients (27.3%) in the epacadostat group 
discontinued because of an adverse event (TEAE in 2 patients; TRAE in 4 patients). 
No tamoxifen-treated patients discontinued because of TEAEs. The remaining 6 
epacadostat-treated patients (27.3%) and 9 tamoxifen-treated patients (45.0%) 
discontinued study drug because of the sponsor’s decision to terminate the study 
early because of slow accrual and a lack of superior efficacy with epacadostat at 
time of interim analysis (Supplement Table 2). These 15 patients were censored for 
the unplanned interim analysis. 
The majority of patients were white (epacadostat, 100%; tamoxifen, 90.0%), and the 
median age overall was 59.0 years. Baseline demographics and disease 
characteristics were generally well balanced across the 2 treatment groups, including 
primary cancer site, number of months from completion of prior first-line 
chemotherapy to the first CA-125 elevation, prior surgery, prior systemic therapy, 
and breast cancer susceptibility gene (BRCA) status. The most common FIGO stage 
at diagnosis was stage IIIC for both treatment groups (64.3% overall; Table 1). 
Efficacy 
At early study termination, epacadostat was not associated with superiority over 
tamoxifen as measured by investigator-assessed PFS. Median PFS was 3.75 
months in the epacadostat group versus 5.56 months in the tamoxifen group. The 
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hazard ratio (HR) for death or disease progression was 1.34 (95% CI, 0.58–3.14; 
P=0.54; Figure 1). For patients who had their first CA-125 elevation 3 to <12 months 
after completion of first-line chemotherapy (baseline stratification factors), median 
PFS was 2.24 months for epacadostat versus 5.48 months for tamoxifen (HR, 1.63 
[95% CI, 0.48–5.50]; P=0.41). For patients with their first CA-125 elevation at ≥12 
months, median PFS was 3.98 and 5.56 months in epacadostat and tamoxifen arms 
(HR, 0.85 [95% CI, 0.26–2.80]; P=0.78), respectively. 
Of evaluable patients, 1 (5.0%) in the epacadostat group and 3 (15.8%) in the 
tamoxifen group had confirmed CA-125 responses. Two additional patients (10.0%) 
in the epacadostat group and 2 (10.5%) in the tamoxifen group had CA-125 
responses but were unconfirmed (ie, ≥50% reduction of CA-125 at only 1 time point; 
Supplement Table 3). The mean best percentage change from baseline in CA-125 
was 36.6% for epacadostat-treated patients and 59.9% for tamoxifen-treated 
patients (Figure 2). 
Overall survival was assessed over the treatment and follow-up phases, during 
which 21 patients (95.5%) receiving epacadostat and all 20 patients (100%) 
receiving tamoxifen discontinued from the study and were censored from the overall 
survival analysis. The remaining 1 patient (4.5%) in the epacadostat group 
completed study drug treatment and the 60-day safety follow-up but subsequently 
died because of disease progression during the survival follow-up, before the 
sponsor’s decision to terminate the study. No tamoxifen-treated patients died at time 
of follow-up before study termination. 
Safety and Tolerability 
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Epacadostat was generally well tolerated. Twenty-two patients received ≥1 dose of 
epacadostat, with a median exposure of 56.0 days and a median total daily dose of 
1200 mg. Twenty patients received ≥1 dose of tamoxifen, with a median exposure of 
61.0 days and a median total daily dose of 40 mg. 
Seventeen patients (77.3%) in the epacadostat group and 15 patients (75.0%) in the 
tamoxifen group experienced TEAEs (Table 2A). The most frequently reported all-
grade TEAE in both groups was fatigue (epacadostat, 36.4%; tamoxifen, 40.0%). Six 
patients (27.3%) in the epacadostat group discontinued study drug because of an 
adverse event; the most frequently reported reason was rash (n=3; all TRAEs). No 
patient in the tamoxifen group discontinued because of an adverse event. 
Seven patients (31.8%) in the epacadostat group and 2 patients (10%) in the 
tamoxifen group had TEAEs of grade ≥3. The most frequently reported grade ≥3 
TEAE in the epacadostat group was maculopapular rash (n=2 [9.1%]). No individual 
TEAE grade ≥3 was reported in >1 patient in the tamoxifen group. 
There were no TEAEs leading to death. One patient in each treatment group had a 
serious adverse event (epacadostat, abdominal pain [4.5%]; tamoxifen, ascites 
[5.0%]). 
As expected based on its mechanism of action, no irAEs were reported in patients 
receiving tamoxifen. In the epacadostat group, the most frequently reported irAEs 
were skin related: 4 patients (18.2%) had rash and 2 patients (9.1%) had pruritus 
(Table 2B). Two patients (9.1%) receiving epacadostat had a grade ≥3 irAE of 
maculopapular rash. 
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The majority of patients had normal haematology and clinical chemistry laboratory 
assessments at baseline, and the values remained normal throughout the study. 
Overall, no clinically meaningful changes or trends in vital signs or ECG findings 
were observed. There were no reports of serotonin syndrome at any time during the 
study.  
Pharmacokinetics 
After oral administration of epacadostat 600 mg BID (n=15), mean (SD) epacadostat 
maximum observed plasma concentration (Cmax), minimum observed plasma 
concentration (Cmin), and area under the plasma concentration-time curve (AUC0-τ) 
were 6.20 (2.68) μM, 0.868 (0.516) μM, and 31.7 (11.7) μM·h, respectively, on day 
15 of cycle 1. Median time to Cmax (tmax) was 1.9 hours postdose (Figure 3). 
Pharmacodynamics 
Samples from 29 patients were available for IDO1 inhibition analysis. In the 
epacadostat group (n=16), the average Kyn level was reduced by 39% from 2010 
nM at cycle 1 day 1 to 1227 nM at cycle 2 day 1, suggesting that treatment with 
epacadostat reduced plasma Kyn levels to within the observed range in healthy 
volunteers (median Kyn, 1499 nM) [25]. In contrast, the average Kyn level was 
reduced by 13% in the tamoxifen group (n=13) during the same period (from 2192 to 
1897 nM).  
In the ex vivo PD analysis that evaluated IDO1 inhibition in IFN-γ– and LPS- 
stimulated whole blood samples, >90% Kyn reduction was observed for at least the 
first 6 hours after epacadostat administration on day 1 of cycle 1 and at all time 
points after epacadostat administration on day 15; average inhibition over the 6 
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hours ranged from 95% to 98% (Figure 4A, 4B). Meanwhile, reductions in Kyn 
levels in the tamoxifen group appeared to be more modest and inconstant, 
evidenced by an average inhibition of 0% to 40% over the 6 hours (data not shown). 
There were no significant differences in inflammatory markers between treatment 
groups at baseline; however, these baseline markers, including C-reactive protein 
(CRP) and interleukin-6, were elevated in both treatment groups compared with 
healthy volunteers (data not shown). This was not unexpected because patients with 
cancer generally have been shown to have elevated CRP and evidence of a chronic 
systemic inflammatory response [26,27]. Although minor changes were observed in 
some analytes during treatment, they were not statistically significant.  
A large number of archival biopsy tissue samples (30 of 32 samples; 94%) were 
positive for IDO1 expression in tumour cells, although relatively low levels of 
expression were detected in the majority of IDO1-positive patients. PD-L1 
expression was observed in only 11 of 31 evaluable samples (35%); all PD-L1–
positive samples were also IDO1-positive. Only 2 samples (6%) were negative for 
expression of both IDO1 and PD-L1. Eighteen samples (58%) were positive for IDO1 
but negative for PD-L1 (Supplement Table 4) . 
 
DISCUSSION 
This was an international, multicentre, randomised, open-label phase 2 study of the 
efficacy, safety, and tolerability of epacadostat versus tamoxifen in women with 
histologically confirmed epithelial ovarian cancer, primary peritoneal carcinoma, or 
fallopian tube cancer who had biochemical recurrence of disease (CA-125 elevation) 
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and no other objective evidence of disease recurrence after complete response with 
first-line chemotherapy. This is the first report, to our knowledge, of the use of 
immunotherapy in patients with early relapse of ovarian cancer and the first study of 
a small-molecule IDO1 enzyme inhibitor as monotherapy in ovarian cancer. Study 
enrolment was stopped at 42 patients out of the planned 110 upon early termination 
by the sponsor based on slow accrual and lack of evidence of superiority for 
epacadostat. The majority of patients who discontinued did so because of disease 
progression. 
At the time of the interim analysis at study termination (with 14 progression events 
on epacadostat, 12 progression events on tamoxifen, and 8 censored events in each 
arm), there was no significant difference in efficacy between epacadostat and 
tamoxifen as measured by investigator-assessed PFS, and PFS was shorter in both 
treatment groups for patients who had early (3 to <12 months) versus later (≥12 
months) CA-125 relapse following previous complete responses. PFS data were 
similar to those reported in a comparable patient sample from a phase 3 trial 
evaluating tamoxifen 20 mg BID versus thalidomide 220 mg daily, suggesting that 
the efficacy of tamoxifen in this study was as expected in this patient population [28]. 
Epacadostat was generally well tolerated. The majority of patients in the epacadostat 
and tamoxifen groups experienced ≥1 TEAE during the study, with fatigue being the 
most frequently reported TEAE in both groups. As expected, given the mechanism of 
action of epacadostat, irAEs were observed in the epacadostat group and were 
primarily skin-related events. There were no TEAEs leading to death. Epacadostat 
PK parameters in this study were comparable to those observed in the 600-mg BID 
dose group in a dose-escalation study (NCT01195311) in which epacadostat 
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monotherapy (dose range, 50 mg once daily to 700 mg BID) was evaluated in 
patients with advanced malignancies [23]. 
Despite epacadostat not showing single-agent activity, it is important to consider the 
timing of this study in the context of immunotherapy development in advanced 
ovarian cancer. Not only is this the first reported study investigating a small-molecule 
IDO1 enzyme inhibitor in ovarian cancer, the protocol development predated other 
clinical investigations with checkpoint inhibitors in this cancer setting. In addition, all 
immune responses are accompanied by (and limited by) the generation of negative 
feedback mechanisms that may suppress immunity; IDO1 is one of many such 
negative feedback mechanisms [29]. IDO1 expression, which is inducible by 
interferon, is part of adaptive immune resistance mechanisms to limit physiologic 
inflammation [30,31] and may have a broad role in combination immunotherapies for 
human malignancies. The concept of evaluating the predictive role of quantitative or 
qualitative IDO1 expression in tumour tissue and immune cells in the tumour 
microenvironment at baseline or during therapy has not been defined but is a goal of 
ongoing studies. Importantly, this study demonstrated a clinically manageable safety 
profile with epacadostat (including irAEs), effective IDO1 inhibition activity at 600 mg 
BID, and frequent IDO1 expression and coexpression with PD-L1 in tumour samples, 
which are all significant considerations given the potential future use of epacadostat 
in this cancer setting – likely as part of immune-based combination therapy. 
Preclinical evidence suggests that IDO1 inhibition may dramatically increase the 
efficacy of various chemotherapeutic agents without increased toxicity, including 
platinum-based compounds and taxanes [32], both of which are recommended for 
ovarian cancers [2]. Although the mechanisms responsible for this potentiation are 
not fully understood, these effects were not observed in T-cell–deficient animals, 
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suggesting that the effects may be due to the disabling of immunosuppressive 
mechanisms within the tumour microenvironment [32]. In addition, the combination of 
high-dose PD-L1 inhibition and cisplatin was associated with tumour burden 
reduction in preclinical models of ovarian cancers [33]. Ongoing clinical studies are 
evaluating anti–PD-1/PD-L1 agents, including pembrolizumab, atezolizumab, and 
avelumab, in combination with chemotherapy in previously untreated patients with 
ovarian cancers or patients who have recurrent disease (NCT02608684, 
NCT02440425, NCT02659384, and NCT02718417) [34]. In the current study, 
coexpression of IDO1 and PD-L1 was apparent in tumour biopsy samples, 
suggesting that combination treatment of a small-molecule IDO1 enzyme inhibitor, 
such as epacadostat, with an immunomodulatory checkpoint inhibitor may be an 
important therapeutic strategy for cancer treatment beyond this clinical setting. Early 
data from the phase 1/2 dose-escalation study of epacadostat plus ipilimumab in 
patients with unresectable or metastatic melanoma (NCT01604889) are promising 
[35] and suggest that combination therapy of IDO1 inhibition and cytotoxic T-
lymphocyte antigen-4 blockade may be considered in advanced ovarian cancer. 
Other studies are currently being conducted to evaluate epacadostat in combination 
with various immunomodulatory agents, including pembrolizumab (in select 
advanced cancers; NCT02178722), nivolumab (in select advanced cancers; 
NCT02327078), durvalumab (in select advanced cancers; NCT02318277), and 
atezolizumab (in non–small-cell lung cancer; NCT02298153). A phase 3 trial of 
epacadostat combined with pembrolizumab in patients with unresectable or 
metastatic melanoma was initiated in 2016 (NCT02752074).  
In conclusion, this is the first study of the IDO1 enzyme inhibitor epacadostat in 
ovarian cancer and also the first report of immunotherapy use in early-relapse 
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ovarian cancer. Epacadostat was generally well tolerated, with manageable irAEs 
and other adverse events. Although epacadostat monotherapy did not exhibit activity 
at the time of interim analysis, additional studies are in progress to assess the 
activity of epacadostat in combination with other immunomodulatory agents. Study 
findings suggest that tamoxifen may play a role in early-relapse ovarian cancer, and 
support the use of tamoxifen as an appropriate control for trials in this patient 
population.   
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TABLES 
Table 1. Baseline Demographics and Clinical Characteristics (mITT Population) 
 
Table 2.  
 
A. TEAEs Reported by ≥3 Patients in Either Treatment Group 
B. Treatment-Emergent irAEs 
 
FIGURES 
Figure 1. PFS Kaplan-Meier curves by investigator assessment using RECIST 1.1 
criteria (mITT population). mITT, modified intent-to-treat; PFS, progression-free 
survival; RECIST, Response Evaluation Criteria in Solid Tumours. 
 
Figure 2. Best percentage change from baseline in CA-125 (modified intent-to-treat 
population).  
 
Figure 3. Mean (SE) epacadostat plasma concentrations on Day 15 of Cycle 1 in 
patients receiving epacadostat 600 mg twice daily.  
 
Figure 4. Mean kynurenine inhibition in whole blood on (A) Day 1 and (B) Day 15 in 
the epacadostat group.  
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TABLES 
Table 1. Baseline Demographics and Clinical Characteristics (mITT Population) 
Characteristic 
Epacadostat 
600 mg BID 
(n=22) 
Tamoxifen 
20 mg BID 
(n=20) 
 
Total 
(N=42) 
Median (range) age, y 61.0 (23.0–78.0) 58.5 (43.0–77.0) 59.0 (23.0–78.0) 
Race, n (%)    
White 22 (100) 18 (90.0) 40 (95.2) 
Asian 0 2 (10.0) 2 (4.8) 
Primary cancer site, n (%)    
Epithelial ovarian cancer 14 (63.6) 13 (65.0) 27 (64.3) 
Primary peritoneal 
carcinoma 
2 (9.1) 2 (10.0) 4 (9.5) 
Primary fallopian tube 2 (9.1) 2 (10.0) 4 (9.5) 
Adenocarcinoma, not 
specified 
2 (9.1) 2 (10.0) 4 (9.5) 
Othera 2 (9.1) 1 (5.0) 3 (7.1) 
Grade, n (%)    
I 0 1 (5.0) 1 (2.4) 
II 0 0 0 
III 10 (45.5) 14 (70.0) 24 (57.1) 
Unknown 12 (54.5) 5 (25.0) 17 (40.5) 
FIGO stage at screening, n 
(%) 
   
IC 1 (4.5) 1 (5.0) 2 (4.8) 
IIIA 5 (22.7) 2 (10.0) 7 (16.7) 
IIIB 0 4 (20.0) 4 (9.5) 
IIIC 16 (72.7) 11 (55.0) 27 (64.3) 
IV 0 2 (10.0) 2 (4.8) 
BRCA status, n (%)    
BRCA1 mutation only 0 1 (5.0) 1 (2.4) 
BRCA2 mutation only 0 0 0 
Both BRCA1 and BRCA2 0 0 0 
Negative 3 (13.6) 4 (20.0) 7 (16.7) 
Unknown 19 (86.4) 15 (75.0) 34 (81.0) 
ECOG PS, n (%)    
0 12 (54.5) 15 (75.0) 27 (64.3) 
1 10 (45.5) 5 (25.0) 15 (35.7) 
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Characteristic 
Epacadostat 
600 mg BID 
(n=22) 
Tamoxifen 
20 mg BID 
(n=20) 
 
Total 
(N=42) 
Time since completion of 
prior first-line chemotherapy 
to CA-125 elevation,b n (%) 
   
3–<12 mo 10 (45.5) 9 (45.0) 19 (45.2) 
≥12 mo 12 (54.5) 11 (55.0) 23 (54.8) 
Prior surgery, n (%) 22 (100) 20 (100) 42 (100) 
Prior systemic therapy, n (%)    
Carboplatinc 19 (86.4) 16 (80.0) 35 (83.3) 
Paclitaxeld 15 (68.3) 14 (70.0) 29 (69.0) 
Cyclophosphamide 7 (31.8) 4 (20.0) 11 (26.2) 
Cisplatine 5 (22.7) 6 (30.0) 11 (26.2) 
Bevacizumab 3 (13.6) 1 (5.0) 4 (9.5) 
Doxorubicin 2 (9.1) 0 2 (4.8) 
Pegylated liposomal 
doxorubicin hydrochloride 
1 (4.5) 0 1 (2.4) 
Gemcitabine 
hydrochloride 
0 1 (5.0) 1 (2.4) 
BID, twice daily; BRCA1, breast cancer 1 gene; BRCA2, breast cancer 2 gene; ECOG PS, Eastern 
Cooperative Oncology Group performance status; FIGO, Federation of International Gynecologists 
and Obstetricians; mITT, modified intent-to-treat. 
aIncludes high-grade serous carcinoma and serous tubal intraepithelial carcinoma, ovarian/primary 
peritoneal, and papillary cystadenocarcinoma. 
bTwo patients (1 in each treatment group) were enrolled under the original protocol (Feb. 28, 2012), 
which enrolled patients who had a 6- to <12-month duration since completion of prior first-line 
chemotherapy and CA-125 elevation. Data for these 2 patients were analysed in the 3- to <12-month 
subgroup. 
cIncludes carboplatin alone and carboplatin + paclitaxel. 
dIncludes paclitaxel alone, paclitaxel + carboplatin, and paclitaxel + cisplatin. Paclitaxel is only 
counted once, but patients may have received paclitaxel as part of 2 separate regimens (ie, paclitaxel 
alone followed by paclitaxel + carboplatin). 
eIncludes cisplatin alone and cisplatin + paclitaxel.  
 29 
Table 2.  
 
A. TEAEs Reported by ≥3 Patients in Either Treatment Group 
Preferred Term, n (%) 
Epacadostat 
600 mg BID 
(n=22) 
Tamoxifen 
20 mg BID 
(n=20) 
All-grade TEAE 17 (77.3) 15 (75.0) 
Fatigue 8 (36.4) 8 (40.0) 
Nausea 6 (27.3) 6 (30.0) 
Rasha 5 (22.7) 0 
Abdominal distension 4 (18.2) 3 (15.0) 
Constipation 4 (18.2) 2 (10.0) 
Vomiting 4 (18.2) 3 (15.0) 
Abdominal pain 3 (13.6) 0 
Arthralgia 3 (13.6) 2 (10.0) 
Decreased appetite 3 (13.6) 4 (20.0) 
Headache 3 (13.6) 3 (15.0) 
Insomnia 3 (13.6) 1 (5.0) 
Dyspnoea 2 (9.1) 3 (15.0) 
BID, twice daily; TEAE, treatment-emergent adverse event. 
aIncludes the following preferred terms: rash maculopapular, rash papular, rash erythematous, and 
rash. 
 
 
B. Treatment-Emergent irAEs 
Preferred Term, n (%) 
Epacadostat 
600 mg BID 
(n=22) 
Tamoxifen 
20 mg BID 
(n=20) 
Patients with any treatment-
emergent irAE 
5 (22.7) 0 
Rasha 4 (18.2) 0 
Pruritus 2 (9.1) 0 
Hyperthermia 1 (4.5) 0 
BID, twice daily; irAE, immune-related adverse event. 
aIncludes the following preferred terms: rash maculopapular, rash erythematous, and rash. 
  
 30 
FIGURES 
Figure 1. PFS Kaplan-Meier curves by investigator assessment using RECIST 1.1 
criteria (mITT population). mITT, modified intent-to-treat; PFS, progression-free 
survival; RECIST, Response Evaluation Criteria in Solid Tumours. 
 
Figure 2. Best percentage change from baseline in CA-125 (modified intent-to-treat 
population).  
 
Figure 3. Mean (SE) epacadostat plasma concentrations on Day 15 of Cycle 1 in 
patients receiving epacadostat 600 mg twice daily.  
 
Figure 4. Mean kynurenine inhibition in whole blood on (A) Day 1 and (B) Day 15 in 
the epacadostat group.  
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Figure 2.  
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Figure 3.  
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Figure 4.  
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SUPPLEMENT 
Table 1. Dose Interruptions, Continuations, and Reductions 
Adverse Event CTCAE 4.03 Grade 
Action with Respect to 
Epacadostat 
Non-irAE clearly not related 
to underlying malignancy or 
intercurrent illness 
3 Interrupt until event is 
resolved to ≤ grade 1; 
restart after a dose 
reduction to 400 mg BIDa 
Non-irAE clearly not related 
to underlying malignancy or 
intercurrent illness 
3 
(second occurrence of same 
event after restart at lower 
dose) 
Discontinue treatment and 
withdraw from study; treat 
symptomatically; schedule 
follow-up visit 
Non-irAE clearly not related 
to underlying malignancy or 
intercurrent illness 
4 Discontinue treatment and 
withdraw from study; 
schedule follow-up visit 
Immune-mediated AEb such 
as enterocolitis, hepatitis, 
neuropathies or dermatitis 
2 Interrupt until event is 
resolved to ≤ grade 1; 
restart after a dose 
reduction to 400 mg BIDa 
Any immune-mediated AEb 3 or higher Discontinue treatment and 
withdraw from study (except 
endocrinopathies)c; treat 
symptomatically; schedule 
follow-up visit 
Immune-mediated, vision 
threatening ocular 
manifestations such as 
uveitis, episcleritis and iritis 
2 or higher Discontinue treatment and 
withdraw from study; treat 
symptomatically; schedule 
follow-up visit 
AE, adverse event; ANA, antinuclear antibody; BID, twice daily; CTCAE, Common Terminology 
Criteria for Adverse Events; irAE, immune-related adverse event; SMA, smooth muscle antibody. 
aIf necessary a 2nd dose reduction to 300 mg BID is permitted if the event recurs. However only 2 
dose reductions are permitted and if a second dose reduction is required this must be discussed with 
the medical monitor before resuming treatment. 
bImmune-related AEs include (but are not limited to) rash/mucositis (including diffuse maculopapular 
rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness 
dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations), enterocolitis, autoimmune 
hepatitis (including positive ANA and SMA), endocrinopathies (including thyroiditis with either hypo- or 
hyperthyroidism, hypophysitis, and either adrenal insufficiency or Cushing’s syndrome), neuropathy 
(including peripheral motor or sensory neuropathy as well as Guillain-Barré syndrome), ocular events 
(uveitis, episcleritis, or iritis), pancreatitis, and sarcoid-like syndrome (diffuse lymphadenopathy with 
non-caseating granulomas on biopsy). Other etiologies for organ dysfunction should be ruled out as 
part of the evaluation. 
cSubjects who develop immune-related endocrinopathies may resume therapy once replacement 
therapy has been initiated. 
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SUPPLEMENT 
Table 2. Patient Disposition (mITT Population) 
Disposition Status, n (%) 
Epacadostat 
600 mg BID 
(n=22) 
Tamoxifen 
20 mg BID 
(n=20) 
 
Total 
(N=42) 
Patients who discontinued 
study drug 
22 (100) 20 (100) 42 (100) 
Primary reason for 
discontinuation from study 
druga 
   
Disease progression 10 (45.5) 11 (55.0) 21 (50.0) 
Adverse event 6 (27.3) 0 6 (14.3) 
Termination by the sponsor 6 (27.3) 9 (45.0) 15 (35.7) 
BID, twice daily; mITT, modified intent-to-treat. 
aNo patients withdrew from the study for reasons of death, consent withdrawal, protocol deviation, lost 
to follow-up, noncompliance, patient decision, investigator decision, pregnancy, lack of efficacy, 
physician decision, missing, or other.  
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SUPPLEMENT 
Table 3. CA-125 Response Rate (mITT Population) 
 
Epacadostat 
600 mg BID 
(n=22) 
Tamoxifen 
20 mg BID 
(n=20) 
 
P Valuea 
CA-125 response, n (%)    
Total evaluable patients 20 (90.9) 19 (95.0)  
Confirmed response 1 (5.0) 3 (15.8) 0.342 
Unconfirmed responseb 2 (10.0) 2 (10.5)  
Non-responders 17 (85.0) 14 (73.7)  
Patients with normal CA-125 
postbaseline, n (%) 
1 (4.5) 4 (20.0)  
Mean (range) best change from 
baseline in CA-125, % 
36.6 (−78.2 to 
359.1) 
59.9 (−93.7 to 
914.4) 
 
BID, twice daily; mITT, modified intent-to-treat. 
aCalculated based on the Fisher exact test comparing the overall response rate between epacadostat 
and tamoxifen. 
bPatients with a decreased CA-125 response that was not confirmed at a second time point.  
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SUPPLEMENT 
Table 4. Protein Expression in Archival Tumour Biopsy Tissue Samples 
Protein Expression, n IDO1-Positive IDO1-Negative Total 
PD-L1–positive 11 0 11 
PD-L1–negative 18 2 20 
PD-L1–not evaluable 1 0 1 
Total 30 2 32 
IDO1, indoleamine 2,3-dioxygenase-1; PD-L1, programmed death-ligand 1. 
